Literature DB >> 11753428

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer.

Enrico L DiGiammarino1, Amanda S Lee, Craig Cadwell, Weixing Zhang, Brian Bothner, Raul C Ribeiro, Gerard Zambetti, Richard W Kriwacki.   

Abstract

The p53 tumor suppressor requires tetramerization to function as an initiator of cell cycle arrest and/or apoptosis. Children in southern Brazil that exhibit an elevated incidence of adrenocortical carcinoma (ACC) harbor an Arg 337 to His mutation within the tetramerization domain of p53 (p53-R337H; 35 of 36 patients). The mutant tetramerization domain (p53tet-R337H) adopts a native-like fold but is less stable than the wild type domain (p53tet-wt). Furthermore, the stability of p53tet-R337H is highly sensitive to pH in the physiological range; this sensitivity correlates with the protonation state of the mutated His 337. These results demonstrate a pH-sensitive molecular defect of p53 (R337H), suggesting that pH-dependent p53 dysfunction is the molecular basis for these cases of ACC in Brazilian children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753428     DOI: 10.1038/nsb730

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  77 in total

Review 1.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

2.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 3.  The molecular genetics of adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Gary D Hammer
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

4.  Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome.

Authors:  Nicholas W Fischer; Aaron Prodeus; James Tran; David Malkin; Jean Gariépy
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

5.  Structural evolution of p53, p63, and p73: implication for heterotetramer formation.

Authors:  Andreas C Joerger; Sridharan Rajagopalan; Eviatar Natan; Dmitry B Veprintsev; Carol V Robinson; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

6.  TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Maoxiang Qian; Xueyuan Cao; Meenakshi Devidas; Wenjian Yang; Cheng Cheng; Yunfeng Dai; Andrew Carroll; Nyla A Heerema; Hui Zhang; Takaya Moriyama; Julie M Gastier-Foster; Heng Xu; Elizabeth Raetz; Eric Larsen; Naomi Winick; W Paul Bowman; Paul L Martin; Elaine R Mardis; Robert Fulton; Gerard Zambetti; Michael Borowitz; Brent Wood; Kim E Nichols; William L Carroll; Ching-Hon Pui; Charles G Mullighan; William E Evans; Stephen P Hunger; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Clin Oncol       Date:  2018-01-04       Impact factor: 44.544

Review 7.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 8.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

9.  Cushing Syndrome in a 6-Month-Old Infant due to Adrenocortical Tumor.

Authors:  Elizabeth B Fudge; Daniel von Allmen; Keith E Volmar; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2009-11-24

10.  Conservation of DNA-binding specificity and oligomerisation properties within the p53 family.

Authors:  Tobias Brandt; Miriana Petrovich; Andreas C Joerger; Dmitry B Veprintsev
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.